BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax 12 is an orally bioavailable selective inhibitor of the anti-apoptotic B-cell lymphoma 2 (Bcl-2) protein, and it provides targeted therapy for the treatment of CLL patients, with a high overall response (80%) [28,29] (Figure 2); however, the development of clinical resistance is associated with its use [30].